The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
The main category of All News Articles.
You can use the search box below to find what you need.
[wd_asp id=1]
From a breakthrough for diabetes to a potential key for heart, kidney, liver, and reproductive health, GLP-1 medications are redefining chronic disease treatment.
The story of GLP-1 receptor agonists began as a chapter in diabetes care, but it is rapidly expanding into a multi-volume saga on managing interconnected chronic conditions. Originally developed to help the body better regulate blood sugar, this class of medications—which includes widely known drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)—has demonstrated effects that reach far beyond the pancreas. By mimicking a natural gut hormone that slows digestion and signals fullness to the brain, these drugs have unlocked a new, systemic approach to treating obesity and its related conditions**, from heart and kidney disease to polycystic ovary syndrome (PCOS). Their rapid rise, coupled with the recent U.S. launch of the first oral GLP-1 pill for obesity, signals a seismic shift in how we approach metabolic and overall health.
The core mechanism of GLP-1 drugs is elegantly tied to natural physiology. They act like the body’s own glucagon-like peptide-1 hormone, which is released after eating. This action triggers a cascade of effects:
This multifaceted approach to regulating metabolism and energy balance is why their benefits extend across multiple organ systems.
A landmark 2026 umbrella review in Nature Communications, synthesizing data from over 5,600 articles, confirmed that GLP-1 receptor agonists show clear trends toward improving outcomes across a wide spectrum of health areas. Their impact is not singular but systemic.
This remains the most dramatic and well-documented effect. Large-scale trials show that newer agents can lead to an average body weight reduction of 15–22%. The recent FDA approval and launch of the first oral GLP-1 pill for obesity—Novo Nordisk’s Wegovy pill—promises to expand access dramatically, with a cash price starting at $149 per month. Clinical trials showed this oral version could lead to an average weight loss of up to 16.6% over 64 weeks.

The cardiovascular benefits are now firmly established. Semaglutide (Wegovy) is approved specifically to reduce the risk of major cardiovascular events—like heart attack, stroke, or cardiovascular death—in adults with obesity and established heart disease. The Nature Communications review corroborates that these drugs show a strong trend toward improving cardiovascular outcomes. Researchers believe these benefits stem not just from weight loss, but also from direct effects on blood vessels, blood pressure, and lipid profiles.
Emerging evidence points to significant renal protection. Slowing the progression of kidney disease is a critical need for many people with diabetes and hypertension, and GLP-1 agonists are showing promise in this arena, as noted in the broad review of their therapeutic potential.
Non-alcoholic fatty liver disease (NAFLD), closely linked to obesity and insulin resistance, may also be positively impacted. Research indicates these drugs can reduce liver fat and inflammation, offering a potential medical therapy for a condition with few treatment options.

Perhaps one of the most profound and personal impacts of GLP-1 therapy is emerging in women’s reproductive health, particularly for the 10% of women affected by Polycystic Ovary Syndrome (PCOS).
PCOS is characterized by insulin resistance, hormonal imbalance, and often obesity, which together can suppress ovulation and cause infertility. GLP-1 drugs attack the root of the problem. By improving insulin sensitivity and promoting significant weight loss, they can help restore hormonal balance and regular menstrual cycles.
A Critical Caution on Contraception and Pregnancy: The fertility-boosting potential comes with a vital warning. These drugs can decrease the effectiveness of oral birth control pills because slower stomach emptying affects the pill’s absorption. Experts strongly recommend using a backup, non-oral contraceptive method (like an IUD, implant, or condoms) to prevent unplanned pregnancies while on GLP-1 therapy. Furthermore, these drugs are not recommended during pregnancy or breastfeeding due to limited safety data. Women planning for pregnancy must work closely with their healthcare team to safely discontinue the medication before trying to conceive.

The promise of these drugs is tempered by the challenges of cost and access. While list prices for injectable versions can approach $1,000 per month, efforts are underway to improve affordability. The recent BALANCE payment model announced by the federal government aims to negotiate lower prices for Medicare and Medicaid programs. Additionally, direct-to-consumer deals, like the $149 per month cash price for the new Wegovy pill, are creating new pathways.
The therapeutic horizon continues to expand. Next-generation agents in development are moving beyond pure GLP-1 agonism. Triple agonists like retatrutide (targeting GLP-1, GIP, and glucagon receptors) and combinations with other hormones like amylin (e.g., CagriSema) promise even greater efficacy for weight loss and metabolic control. The rise of oral small-molecule GLP-1 agonists will likely improve adherence and choice for patients.
GLP-1 receptor agonists represent a fundamental shift from treating individual symptoms to addressing the interconnected root causes of many chronic diseases: metabolic dysfunction and obesity. Their benefits for the heart, kidneys, liver, and reproductive system underscore that improving metabolic health is improving whole-body health.

However, they are powerful medications, not magic bullets. They carry risks, including gastrointestinal side effects and a potential increased risk for certain conditions like gallbladder disease. Their success depends on being part of a holistic plan that includes sustainable nutrition, exercise, and behavioral changes—habits that patients can maintain long after medication is discontinued, especially when preparing for life events like pregnancy.
As access broadens and science advances, the true “miracle” of GLP-1 drugs may ultimately be how they have reframed our understanding of disease, compelling both medicine and society to treat the whole person, not just a single diagnosis.
Disclaimer
The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.
Toronto, Canada, January 9th, 2026, Chainwire
DBTC DeFi today announced the launch of its fully automated decentralized finance platform, designed to generate daily yield without requiring trading, speculation, or ongoing user intervention. In a fast-moving market, where investors often struggle to respond to volatility in real time, DBTC DeFi introduces a system that aims to simplify yield generation by eliminating the need to time the market or actively manage positions.
Why DBTC DeFi Exists
DBTC DeFi was developed to provide a system aimed at generating consistent daily yield, without requiring users to make time-sensitive decisions. The protocol is designed to operate without the need for chart analysis, hardware management, or market timing.
How DBTC DeFi Works
The process is designed to function without technical setup or ongoing user decisions, aiming to provide consistent, automated output.
Key Features of DBTC DeFi
Structured Mechanism Over Market Speculation
DBTC DeFi operates through a structured execution model, rather than relying on speculative investment strategies. The system is designed to function independently of market conditions, with its yield mechanism not dependent on price forecasts or market timing by users.
Starting in Minutes
Sample Investment Structures:
About DBTC DeFi
DBTC DeFi is a leading decentralised finance platform that enables users to generate daily yield through fully automated, hands-off systems. By leveraging global green-energy infrastructure and secure technology, DBTC DeFi offers a reliable and eco-friendly investment solution.
Users can visit: https://dbtcdefi.com and Download the DBTC DeFi App now.
DBTC DeFi
info@dbtcdefi.com
Select market data provided by ICE Data Services. Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc.Copyright © 2026, American Bankers Association. CUSIP Database provided by FactSet Research Systems Inc. All rights reserved. SEC fillings and other documents provided by Quartr.© 2026 TradingView, Inc.
The GBPJPY pair lost the bullish momentum due to stochastic exit from the overbought level, which forces it to delay the bullish attack by reaching below 211.30 level, which keeps forming an important obstacle against the bullish attempts.
We expect providing new mixed trading with a chance of attacking the minor bullish channel’s support at 210.10, breaking this support makes us expect targeting extra corrective stations that might begin at 209.45 and 208.80, while the trading rally above the obstacle will increase the chances of recording new gains by targeting 212.55 and 213.75 level.
The expected trading range for today is between 210.10 and 211.50
Trend forecast: Fluctuated within the bullish trend
Lemme is continuing its strong launch pipeline with the introduction of Creatine Body Toning Gummies.
Each serving delivers 5 grams of micronized creatine monohydrate with clinically studied AstraGin to support lean muscle tone, strength, recovery and cognitive health. Lemme Creatine will be available exclusively at lemmelive.com on Jan. 13, priced at $30.
In an interview, Lemme cofounder Kourtney Kardashian Barker said: “Many people think of creatine as something that bulks you up, but it’s actually one of the most powerful nutrients in the world in that it can increase strength, recovery and support brain health. Research shows that women naturally produce lower creatine than men, so they’ll see even greater advantages from taking the supplements.”
Often creatine comes in powder form.
“We saw a huge gap in the market,” continued Kardashian Barker, who, as reported, is the recipient of the WWD Style Award for Wellness Entrepreneur of the year. “Creatine is one of the most researched ingredients, but it’s always been marketed to men in big tubs of powder and we knew we wanted it in a format that was more approachable.”
Kardashian Barker debuted the supplement brand Lemme in 2022 with longtime friend Simon Huck. The first products were easy to understand and fun formulas like Lemme Sleep, $30, and Lemme Debloat, $30.
Over the past few years, Lemme has been expanding its retail footprint, launching at Ulta Beauty in 2023, Target in 2024 and entering 2,000 Walmart stores at the beginning of this month, as well as online.
Its launch pipeline has been particularly active of late, too, with the brand releasing colostrum supplements in November and a fat-burning gummy in December.
XRP rallied 25% in the first week 2026 from $1.77 December low to $2.38 January 6—37% below July 2025 ATH $3.65 with $1.3B ETFs absorbed in 50 d
Exchange balances dropped 57% from 4B XRP to 1.7B in 2025. This marks one of the largest annual supply reductions on record.
XRP’s path to $4 requires a BlackRock XRP ETF filing credibility shock, RLUSD scaling banking rails, and 3-4 Fed rate cuts.
Have You read The New Report Shaking Up Retirement Plans? Americans are answering three questions and many are realizing they can retire earlier than expected.
XRP (CRYPTO: XRP) trades near $2.30 after rallying 25% in the first week of 2026, recovering sharply from December lows near $1.77. Despite this momentum, XRP remains 37% below its July 2025 all-time high of $3.65. The question for 2026 is straightforward: Can institutional demand push XRP to $4, or will $2.50 be the ceiling?
The bulls see renewed institutional conviction driving a full re-rating. They target $4-$8 based on Standard Chartered’s projection and the $1.3 billion already absorbed by XRP ETFs in just 50 days. The bears argue XRP has already shown its limits. They point to XRP’s large supply and weak value capture as factors that could cap upside to $2.50-$3.00. The answer comes down to institutional behavior: Do they accumulate for years, or trade volatility and move on?
After a brutal Q4 2025 that saw XRP slide from its July peak of $3.65 to December lows near $1.77, the token staged a remarkable recovery in early January. XRP opened 2026 at $1.84 and surged to $2.38 by January 6—a 25-28% gain in just one week. The rally outpaced most major cryptocurrencies and brought renewed attention to XRP’s institutional narrative.
The move coincided with several catalysts: continued ETF inflows, improving regulatory sentiment, and a broader risk-on rotation in crypto markets. From a technical perspective, XRP broke through resistance at $2.00 and briefly tested $2.40 before pulling back. The token now trades around $2.27-$2.30, consolidating recent gains.
The most compelling development was the unprecedented success of spot ETF launches. In just 50 days since mid-November, XRP ETFs absorbed $1.3 billion with 43 consecutive trading days of positive inflows and zero outflows. That makes XRP the second-fastest crypto ETF to cross the billion-dollar threshold after Bitcoin.
Seven spot XRP ETFs now trade in the United States with combined assets under management exceeding $2 billion and approximately 793 million XRP tokens locked in custody. Major issuers include Canary Capital (XRPC), Grayscale (GXRP), Bitwise (XRP), Franklin Templeton (XRPZ), REX-Osprey (XRPR), 21Shares (TOXR), and newer entrants.
Silver price (XAG/USD) edges higher after two days of losses, trading around $77.20 per troy ounce during the Asian hours on Friday. The prices of the precious metals, including Silver hold ground as traders adopt caution ahead of key US jobs data amid elevated geopolitical tensions.
Traders await the US Nonfarm Payrolls (NFP) report, which is expected to offer further insight into labor market conditions and the Federal Reserve’s (Fed) policy outlook. December NFP is forecast to show job gains of 60,000, down from 64,000 in November.
The dollar-denominated Silver could face further challenges as the US Dollar (USD) strengthens following the release of US weekly labor market data. The US Department of Labor (DOL) reported on Thursday that Initial Jobless Claims rose modestly to 208,000 in the week ended January 3, slightly below market expectations of 210,000 but above the previous week’s revised 200,000.
Meanwhile, the grey metal remains on track for a weekly gain of over 6%, underpinned by rising geopolitical tensions that have boosted safe-haven demand. President Trump warned of a forceful response to any Iranian violence against protesters, following recent US actions in Venezuela and threats to use military force to seize control of Greenland.
Silver is a precious metal highly traded among investors. It has been historically used as a store of value and a medium of exchange. Although less popular than Gold, traders may turn to Silver to diversify their investment portfolio, for its intrinsic value or as a potential hedge during high-inflation periods. Investors can buy physical Silver, in coins or in bars, or trade it through vehicles such as Exchange Traded Funds, which track its price on international markets.
Silver prices can move due to a wide range of factors. Geopolitical instability or fears of a deep recession can make Silver price escalate due to its safe-haven status, although to a lesser extent than Gold’s. As a yieldless asset, Silver tends to rise with lower interest rates. Its moves also depend on how the US Dollar (USD) behaves as the asset is priced in dollars (XAG/USD). A strong Dollar tends to keep the price of Silver at bay, whereas a weaker Dollar is likely to propel prices up. Other factors such as investment demand, mining supply – Silver is much more abundant than Gold – and recycling rates can also affect prices.
Silver is widely used in industry, particularly in sectors such as electronics or solar energy, as it has one of the highest electric conductivity of all metals – more than Copper and Gold. A surge in demand can increase prices, while a decline tends to lower them. Dynamics in the US, Chinese and Indian economies can also contribute to price swings: for the US and particularly China, their big industrial sectors use Silver in various processes; in India, consumers’ demand for the precious metal for jewellery also plays a key role in setting prices.
Silver prices tend to follow Gold’s moves. When Gold prices rise, Silver typically follows suit, as their status as safe-haven assets is similar. The Gold/Silver ratio, which shows the number of ounces of Silver needed to equal the value of one ounce of Gold, may help to determine the relative valuation between both metals. Some investors may consider a high ratio as an indicator that Silver is undervalued, or Gold is overvalued. On the contrary, a low ratio might suggest that Gold is undervalued relative to Silver.
EUR/JPY has recovered its recent losses registered in the previous session, trading around 183.20 during the Asian hours on Friday. The technical analysis of the daily chart suggests that the 14-day Relative Strength Index (RSI) at 54 (neutral) signals steady momentum after easing from overbought. RSI edging higher toward the mid-50s supports stabilization without signaling a stretch.
The 50-day Exponential Moving Average (EMA) rises to 181.43, underpinning the medium-term uptrend. The nine-day EMA has slipped and now caps intraday advances, pointing to consolidation above the 50-day line. The backdrop favors dip-buying while the rising medium-term average holds.
A close back above the nine-day EMA at 183.34 would improve near-term traction toward overhead barriers around the all-time high of 184.95, which was recorded on December 22, aligned with the psychological level of 185.00.
Failure to reclaim the short-term average would leave the cross vulnerable to a deeper mean-reversion phase. The EUR/JPY cross may navigate the region around the initial support at the four-week low of 181.57, recorded on December 17, followed by the 50-day EMA at 181.43. Holding above the medium-term average preserves the broader bullish bias.
The table below shows the percentage change of Euro (EUR) against listed major currencies today. Euro was the strongest against the Japanese Yen.
| USD | EUR | GBP | JPY | CAD | AUD | NZD | CHF | |
|---|---|---|---|---|---|---|---|---|
| USD | -0.05% | 0.02% | 0.16% | 0.10% | 0.07% | 0.14% | 0.00% | |
| EUR | 0.05% | 0.06% | 0.20% | 0.14% | 0.12% | 0.18% | 0.05% | |
| GBP | -0.02% | -0.06% | 0.15% | 0.08% | 0.05% | 0.12% | -0.02% | |
| JPY | -0.16% | -0.20% | -0.15% | -0.05% | -0.09% | -0.03% | -0.16% | |
| CAD | -0.10% | -0.14% | -0.08% | 0.05% | -0.04% | 0.03% | -0.10% | |
| AUD | -0.07% | -0.12% | -0.05% | 0.09% | 0.04% | 0.07% | -0.07% | |
| NZD | -0.14% | -0.18% | -0.12% | 0.03% | -0.03% | -0.07% | -0.13% | |
| CHF | -0.00% | -0.05% | 0.02% | 0.16% | 0.10% | 0.07% | 0.13% |
The heat map shows percentage changes of major currencies against each other. The base currency is picked from the left column, while the quote currency is picked from the top row. For example, if you pick the Euro from the left column and move along the horizontal line to the US Dollar, the percentage change displayed in the box will represent EUR (base)/USD (quote).
(The technical analysis of this story was written with the help of an AI tool.)
AURORA, COLORADO, Jan. 08, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing. This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you.
AquaFit, a capsule-format dietary supplement marketed in the weight management category, has attracted consumer attention in January 2026 as seasonal patterns in supplement searches often increase during New Year health initiatives. According to the company, the formulation emphasizes a metabolism-focused narrative and thermogenic research references, alongside an ingredient profile described by the company in its published materials.
This report summarizes publicly available label information and published research context; it does not evaluate clinical outcomes or product performance. The manufacturer positions AquaFit around research examining the relationship between metabolic rate patterns in adipose tissue and cellular energy expenditure. The company references a 2019 research discussion published in Scientific Reports associated with circadian regulation in human white adipose tissue that examined how metabolic timing patterns relate to fat cell activity in research settings. The research did not evaluate AquaFit or any dietary supplement and does not establish clinical outcomes.
Consumers researching AquaFit often encounter information about its capsule-based delivery format and ingredient profile described as including nine botanical extracts plus essential minerals.
What AquaFit Is and How the Company Positions the Formula
According to the company, AquaFit is a dietary supplement marketed in a capsule format. In the company’s published materials, the product’s messaging emphasizes thermogenic research references within the broader context of metabolic health discussions.
Thermogenesis is a metabolic process that has been extensively studied for its role in energy expenditure. Research published examining green tea catechins and their effects on 24-hour energy expenditure documented how certain botanical compounds influence metabolic rate in controlled settings. These researchers have no affiliation with AquaFit, but their work contributes to broader scientific discussions around thermogenesis and its relationship to weight management research.
According to the manufacturer, AquaFit contains ingredients selected based on published research examining their potential relationships to metabolic function, glucose utilization, and energy balance. The capsule format is positioned by the company as a convenient delivery method.
AquaFit and the Metabolic Research Narrative
The company references a 2019 research discussion published in Scientific Reports that examined circadian regulation in human white adipose tissue through transcriptome and metabolic network analysis. The research did not evaluate AquaFit or any dietary supplement and does not establish clinical outcomes.
The referenced research examined how fat cells operate on different metabolic cycles throughout the day, with metabolic activity patterns varying based on circadian rhythms. According to coverage in Science Daily, the research suggested that cellular metabolism in adipose tissue may have relationships to timing patterns and hormonal fluctuations. Published research has examined how metabolic rate, nutrient processing, and energy expenditure relate to cellular function in various tissue types.
This research builds on earlier published studies. A 2006 study published in the Journal of the American Dietetic Association examined low-fat dietary patterns and weight change over seven years in the Women’s Health Initiative Dietary Modification Trial. A 2021 study published in the American Journal of Clinical Nutrition examined relationships between dietary factors and body composition. Research published in peer-reviewed literature has examined how various compounds may relate to metabolic function and energy balance.
The metabolism-related hypothesis discussed in published research suggests that certain botanical compounds play roles in thermogenic function by influencing cellular energy pathways. Research has documented that metabolic rate changes with age, which has been associated with various age-related weight management considerations in some populations.
Consumers evaluating AquaFit should understand that the circadian adipose tissue research investigated physiological mechanisms and cellular processes rather than evaluating specific supplement formulations. AquaFit as a complete product has not been subjected to clinical trials. The manufacturer references this research as the conceptual foundation for the formula’s design.
AquaFit Ingredient Profile: Research Context and Formulation Design
According to the company’s published formulation details, AquaFit contains ingredients selected based on published research examining their potential relationships to various biological processes. Consumers researching AquaFit often encounter detailed ingredient information in the manufacturer’s materials.
The product label lists a proprietary botanical blend totaling 276 mg, plus zinc (5.5 mg as zinc gluconate) and chromium (0.05 mg as chromium picolinate). This labeling approach is permitted under current FDA regulations but may limit direct comparison to dosages used in published research. The proprietary blend includes the following components:
Alpha Lipoic Acid
Alpha lipoic acid is a compound produced naturally by the body that functions as a cellular antioxidant and mitochondrial cofactor. Published research has examined alpha lipoic acid for its relationships to various metabolic processes. A systematic review and meta-analysis published in peer-reviewed literature examined alpha lipoic acid’s effects on body weight, finding associations with modest weight reduction in some study populations. A 2012 study published in Obesity Reviews examined the compound’s relationships to energy metabolism and oxidative stress markers. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Green Tea Extract (98% Polyphenols, 80% Catechins, 50% EGCG)
Green tea (Camellia sinensis) extract has extensive documentation in metabolic research. A 1999 study published in the American Journal of Clinical Nutrition examined the efficacy of green tea extract rich in catechin polyphenols and caffeine in increasing 24-hour energy expenditure and fat oxidation in humans. A 2007 study published in Obesity examined a green tea extract high in catechins and its effects on body fat and cardiovascular risks in study participants. A 2013 meta-analysis published in the American Journal of Clinical Nutrition examined the effect of green tea on glucose control and insulin sensitivity across 17 randomized controlled trials. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Milk Thistle Seed Extract (80% Silymarin)
Milk thistle (Silybum marianum) and its active compound silymarin are primarily known for their traditional use in supporting liver function. Published research has examined silymarin for its antioxidant properties and relationships to hepatic metabolism. A 2016 review examined silymarin’s effects on metabolic parameters in various study populations. The liver plays a central role in processing nutrients, metabolizing fats, and regulating blood sugar, which has led researchers to investigate relationships between liver health compounds and metabolic function. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Berberine HCL (97% from Berberis aristata Root)
Berberine is an alkaloid extracted from plants including Berberis aristata that has been used in traditional medicine systems for centuries. Modern research has focused on its potential effects on glucose metabolism and related metabolic markers. A meta-analysis published in peer-reviewed literature examined multiple randomized controlled trials involving berberine supplementation, finding associations with improvements in certain metabolic markers in some study populations. Mechanistic research suggests berberine may influence metabolic function through effects on cellular energy pathways, though the exact mechanisms continue to be studied. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Resveratrol (from Polygonum cuspidatum Root Extract)
Resveratrol is a polyphenol found in grapes, berries, and other plants that has been studied for antioxidant properties and potential effects on cellular metabolism. Published research has examined resveratrol’s relationships to various metabolic processes including energy expenditure and lipid metabolism. A 2015 meta-analysis examined resveratrol supplementation’s effects on metabolic parameters across multiple studies. Research has investigated resveratrol’s potential activation of certain cellular pathways related to energy metabolism. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Cayenne Fruit (40,000 Heat Units)
Cayenne pepper (Capsicum annuum) contains capsaicin, which has been researched for its thermogenic properties. A 2012 study published in Chemical Senses examined capsaicin’s effects on energy expenditure and substrate oxidation. Published research has documented that capsaicin consumption has been associated with temporary increases in metabolic rate through thermogenic mechanisms in some study populations. A 2017 meta-analysis examined capsaicinoid supplementation’s relationships to energy intake and expenditure. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Korean Ginseng (8% Ginsenosides)
Panax ginseng has extensive documentation in traditional practices spanning centuries. A 2013 review published in specialized literature examined research discussions on ginseng’s relationships to various physiological processes including energy metabolism. Published research has examined ginsenosides, the active compounds in ginseng, for potential effects on glucose metabolism and energy balance. A 2014 study examined ginseng’s relationships to fatigue and energy levels in various populations. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Banaba Leaf Extract (2% Corosolic Acid)
Banaba (Lagerstroemia speciosa) is a traditional Asian botanical used for metabolic support. Published research has examined corosolic acid, the primary active compound in banaba, for its potential effects on glucose transport. A 2012 review examined banaba leaf extract’s relationships to blood sugar regulation in various study populations. Research has investigated corosolic acid’s potential influence on cellular glucose uptake mechanisms. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Mineral Components: Zinc and Chromium
According to the company, AquaFit includes two essential minerals. Zinc has been examined in published research for its relationships to various metabolic processes including protein synthesis and enzyme function. A 2013 study examined zinc’s relationships to metabolic markers in various populations. Chromium, particularly as chromium picolinate, has been studied for its involvement in insulin signaling and macronutrient metabolism. According to the National Institutes of Health Office of Dietary Supplements, chromium is involved in the action of insulin, a hormone critical for metabolism and storage of carbohydrate, fat, and protein in the body. A 2017 meta-analysis examined chromium supplementation’s effects on body composition parameters. These studies examine isolated compounds or biological mechanisms and do not evaluate AquaFit as a finished dietary supplement.
Manufacturing and Regulatory Context for AquaFit
According to the company, AquaFit is manufactured in the United States for AquaFit, Natures Formulas, based in Aurora, Colorado. The manufacturer states that ingredients are sourced according to quality specifications and that the product formulation follows established supplement manufacturing protocols.
Consumers researching dietary supplements should understand that the FDA does not approve dietary supplements before they reach the market. The regulatory framework for supplements differs from medications, with the Dietary Supplement Health and Education Act placing responsibility on manufacturers for safety and accurate labeling.
According to the company, AquaFit uses vegetable capsules (hypromellose), making it suitable for those following vegetarian dietary preferences. Other ingredients include microcrystalline cellulose, magnesium stearate, and silicon dioxide.
Label directions describe a once-daily capsule format; readers should follow the product label and consult a qualified healthcare professional for individualized guidance.
Safety Information and Interaction Considerations
Some ingredients commonly discussed in metabolic supplement research may be relevant for individuals taking medications or managing health conditions. Published research frequently discusses berberine, chromium, and alpha lipoic acid in relation to glucose metabolism, and green tea extracts may contain caffeine. Individuals who take prescription medications or have medical conditions should consult a qualified healthcare professional before using dietary supplements.
The product label states the following cautions: Do not exceed recommended dose. Not for use by those under the age of 18 or pregnant or nursing mothers. Consult with a physician prior to use especially if you are taking a medication or have a medical condition.
Distribution Information
According to the company, AquaFit is offered through its official website, where current availability, shipping information, and policy terms are published and subject to change. According to the company’s published policy pages, AquaFit lists refund and return terms on its official website, and those terms may change; consumers are encouraged to review current details directly before making any purchase decision.
Market Context: Weight Management Supplement Category
Consumers researching weight management approaches encounter numerous options including single-ingredient supplements, multi-ingredient formulations, prescription medications, and various dietary and exercise programs. Traditional supplement approaches have emphasized particular botanicals such as green tea extract or conjugated linoleic acid as primary ingredients. These have varying levels of research documentation, with study results showing mixed outcomes across different research designs.
Prescription medications represent a different category with distinct regulatory pathways. These medications undergo clinical trial processes and regulatory review procedures that differ from dietary supplement pathways.
According to the company, AquaFit’s positioning emphasizes thermogenic research references and metabolic support research discussions within the broader weight management supplement category. The capsule format represents one delivery method option within the broader supplement category.
What Research and Public Information Do and Do Not Show About AquaFit
Consumers evaluating AquaFit should understand several important distinctions about research and evidence:
AquaFit as a complete formulation has not been subjected to clinical trials. The manufacturer references published research on individual ingredients and physiological mechanisms, but these studies examined isolated compounds or biological processes rather than evaluating the finished AquaFit product.
Published research on ingredients represents investigation of individual substances under controlled conditions. The presence of researched ingredients in a formulation does not predict outcomes from the complete product. Ingredient research and finished product outcomes represent different categories of evidence.
Individual responses to dietary supplements vary significantly based on numerous factors including baseline characteristics, lifestyle variables, genetic factors, concurrent medications, health status, and other individual considerations. Research documenting group-level statistical associations in controlled studies does not predict individual experiences.
The company references research as the conceptual foundation for formulation design. This represents the manufacturer’s interpretation of published science rather than direct evidence of product efficacy. Consumers should distinguish between research informing formulation strategy and research documenting finished product outcomes.
One characteristic of the AquaFit formula worth noting: the use of a proprietary blend. While the total blend weight is listed (276 mg), individual ingredient amounts within the blend are not specified on the label. This labeling approach is permitted under current FDA regulations but may limit direct comparison to dosages used in published research.
Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Weight management concerns should be evaluated by qualified healthcare professionals. Any health management decisions should occur with physician guidance.
Consumer Decision Framework and Evaluation Considerations
Consumers considering nutritional approaches to weight management encounter questions about appropriateness, expectations, and alignment with individual circumstances. AquaFit represents one option within a broader landscape of supplement and lifestyle approaches.
Consumers researching AquaFit often have various characteristics and motivations. Some seek nutritional support approaches while maintaining active lifestyles. Others take proactive approaches to metabolic health maintenance. Some prefer multi-ingredient formulas. Some are drawn to formulations emphasizing thermogenic and metabolic research. Individual priorities and circumstances vary significantly.
Consumers for whom AquaFit may not be appropriate include those requiring medical intervention for obesity or metabolic disorders, those with diagnosed medical conditions requiring physician oversight, individuals seeking evidence from product-specific clinical trials, individuals with sensitivities to caffeine or botanical extracts, those who prefer single-ingredient approaches for precise dosing, or those taking multiple medications or managing complex health situations.
Before choosing any dietary supplement, healthcare provider consultation is recommended to ensure appropriate oversight and informed decision-making. Lifestyle approaches including caloric balance, dietary patterns, physical activity, sleep quality, and stress management significantly relate to weight management outcomes.
Contact Information
For questions about AquaFit, according to the company’s published information, customer service is available through:
Product Support Email: support@buyaquafit.com
Phone: 1-888-254-0425 (7AM to 9PM, 7 days a week)
Physical Address: AquaFit, 19655 E 35th Dr #100, Aurora, CO 80011, USA
Readers may view the current AquaFit offer (official AquaFit page) to review manufacturer-published label details, ingredient disclosures, and policy information.
Regulatory Environment and Industry Context
The dietary supplement industry operates under regulatory frameworks that differ from pharmaceutical regulation. The FDA’s authority over dietary supplements differs significantly from medication oversight. Supplements do not require pre-market approval processes, though manufacturers bear responsibility for safety and label accuracy. Post-market surveillance systems monitor safety through adverse event reporting mechanisms.
Recent years have included regulatory attention to health claim categories for various supplement types. The Federal Trade Commission monitors advertising representations, requiring that marketing claims have substantiation.
Consumers should review current information about any supplement’s regulatory status and manufacturing practices before making purchase decisions. Weight management concerns should be evaluated by qualified healthcare professionals. Health management approaches should be discussed with physicians.
Approaches to maintaining healthy weight include balanced caloric intake, dietary patterns emphasizing whole foods, regular physical activity, adequate sleep, stress management, and prompt discussion of weight concerns with qualified healthcare providers.
Disclaimers
FDA Health Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. Always consult your physician before starting any new supplement, especially if you have existing health conditions, take medications, or are pregnant or nursing.
Results May Vary: Individual results will vary based on factors including age, baseline health condition, lifestyle factors, consistency of use, genetic factors, current medications, and other individual variables. Ingredient-level research does not predict outcomes from any specific finished product.
Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you.
Pricing and Policy Disclaimer: All information was accurate at the time of publication (January 2026) but is subject to change. Always verify current pricing, terms, and policies on the official AquaFit website before making decisions.
Publisher Responsibility: The publisher has made every effort to ensure accuracy at the time of publication. Readers are encouraged to verify all details directly with AquaFit and their healthcare provider before making decisions.
Related Links:
Contact: AquaFit Customer Support 19655 E 35th Dr #100 Aurora, CO 80011, USA Phone: 1-888-254-0425 Email: support@buyaquafit.com
The British pound, of course, has drifted a little bit lower. We are in an area of consolidation. I don’t think that changes today. You could, in theory, see a little bit of a bounce when we get closer to 1.34, but really, I think this is the domain of short-term traders more than anything else, with 1.35 being a bit of a magnet for price.
The Bank of England is expected to cut rates as well, but it is expected to do so in a much slower and gradual manner than the market once thought, hence the British pound’s strength over the last couple of months. I think this is a currency that, relatively speaking, at least will fare better than many others against the greenback.
The euro has climbed slightly against the British pound as we continue our bounce from the 200-day EMA, but I will direct you to my analysis from a couple of days ago. I think we’re going to start drifting towards the 0.8720 area and then maybe see some exhaustion that we can start shorting again.
While the Bank of England is expected to cut rates, it’s doing so at a much slower pace, and this, of course, is in comparison to the ECB, which is basically on hold, so we already know that the interest rate differential will continue to favor the pound for some time. That doesn’t necessarily mean that we fall apart. I just think that you’re going to continue to see more of a rally and then a fade type of situation going forward.
For a look at all of today’s economic events, check out our economic calendar.